A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Astellas Pharma Inc
St. Jude Children's Research Hospital
Guangdong Provincial People's Hospital
National Health Research Institutes, Taiwan
NRG Oncology
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
University of Wisconsin, Madison
SWOG Cancer Research Network
Eastern Cooperative Oncology Group
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ipsen
Hoosier Cancer Research Network
University of Michigan Rogel Cancer Center
AstraZeneca
Georgetown University
Tianjin Medical University Cancer Institute and Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
ImmunityBio, Inc.
Revolution Medicines, Inc.
Massachusetts General Hospital
National Health Research Institutes, Taiwan
Fudan University
Affiliated Cancer Hospital of Shantou University Medical College
The First Affiliated Hospital of Zhengzhou University
The Methodist Hospital Research Institute
Federation Francophone de Cancerologie Digestive
University Hospital, Ghent
GERCOR - Multidisciplinary Oncology Cooperative Group
RenJi Hospital
West China Hospital
Ipsen
Big Ten Cancer Research Consortium
AIO-Studien-gGmbH
Peking University Cancer Hospital & Institute
Hebei Medical University Fourth Hospital
Affiliated Hospital of Nantong University
Chinese PLA General Hospital
The First Affiliated Hospital with Nanjing Medical University
Emory University
Akeso
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sun Yat-sen University
Ruijin Hospital
Hebei Medical University Fourth Hospital
BioLineRx, Ltd.
CSPC Ouyi Pharmaceutical Co., Ltd.
West China Hospital
West China Hospital
Fudan University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine